



## Combining trauma script exposure with tDCS to alleviate symptoms of posttraumatic stress disorder: A two-arm randomized sham-controlled multicenter trial

Noémie Eyraud, Pierre Poupin, Marc Legrand, Agnès Caille, Anne Sauvaget, Samuel Bulteau, Bénédicte Gohier, Ghina Harika-Germaneau, Dominique Drapier, Nematollah Jaafari, et al.

### ► To cite this version:

Noémie Eyraud, Pierre Poupin, Marc Legrand, Agnès Caille, Anne Sauvaget, et al.. Combining trauma script exposure with tDCS to alleviate symptoms of posttraumatic stress disorder: A two-arm randomized sham-controlled multicenter trial. *Brain Stimulation*, 2024, 17 (3), pp.591-593. 10.1016/j.brs.2024.04.018 . inserm-04645605

**HAL Id: inserm-04645605**

**<https://inserm.hal.science/inserm-04645605v1>**

Submitted on 11 Jul 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Combining trauma script exposure with tDCS to alleviate symptoms of Posttraumatic Stress Disorder: a two-arm randomized sham-controlled multicenter trial.**

Noémie Eyraud <sup>1\*</sup>, Pierre Poupin <sup>2\*</sup>, Marc Legrand <sup>1</sup>, Agnès Caille <sup>2</sup>, Anne Sauvaget <sup>3</sup>, Samuel Bulteau <sup>3</sup>, Bénédicte Gohier <sup>4</sup>, Ghina Harika-Germaneau <sup>6</sup>, Dominique Drapier <sup>5</sup>, Nematollah Jaafari <sup>6</sup>, Olivier Bodic <sup>7</sup>, Bruno Brizard <sup>1</sup>, Valérie Gissot <sup>2</sup>, Catherine Belzung <sup>1</sup>, Jean-Baptiste Courtine <sup>8</sup>, Wissam El-Hage <sup>1, 2, 8, †</sup>

<sup>1</sup> INSERM, Imaging Brain & Neuropsychiatry iBraIN U1253, Université de Tours, 37032 Tours, France ([noemie.eyraud@univ-tours.fr](mailto:noemie.eyraud@univ-tours.fr), [marc.legrand@univ-tours.fr](mailto:marc.legrand@univ-tours.fr), [bruno.brizard@univ-tours.fr](mailto:bruno.brizard@univ-tours.fr), [catherine.belzung@univ-tours.fr](mailto:catherine.belzung@univ-tours.fr))

<sup>2</sup> CIC 1415, CHRU de Tours, INSERM, Tours, France ([pierre.poupin@univ-tours.fr](mailto:pierre.poupin@univ-tours.fr), [agnes.caille@univ-tours.fr](mailto:agnes.caille@univ-tours.fr), [valerie.gissot@univ-tours.fr](mailto:valerie.gissot@univ-tours.fr))

<sup>3</sup> Nantes Université, CHU Nantes, Movement - Interactions - Performance MIP, UMR INSERM 1246, MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Nantes, France ([Anne.SAUVAGET@chu-nantes.fr](mailto:Anne.SAUVAGET@chu-nantes.fr), [Samuel.BULTEAU@chu-nantes.fr](mailto:Samuel.BULTEAU@chu-nantes.fr), [olivier.bodic@chu-nantes.fr](mailto:olivier.bodic@chu-nantes.fr))

<sup>4</sup> Department of Psychiatry, University Hospital, Angers, France; Université d'Angers, LPPL, SFR CONFLUENCES, F-49000 Angers, France ([begohier@chu-angers.fr](mailto:begohier@chu-angers.fr))

<sup>5</sup> CH Guillaume Regnier, PHUPA, Rennes, France ([dominique.drapier@univ-rennes1.fr](mailto:dominique.drapier@univ-rennes1.fr))

<sup>6</sup> Université de Poitiers, URC CH Henri Laborit, Colcilco CeRCA CNRS UMR 7295, Poitiers, France ([nemat.jaafari@ch-poitiers.fr](mailto:nemat.jaafari@ch-poitiers.fr))

<sup>7</sup> CHU Nantes, Medical and psychological emergency unit (CUMP 44), Nantes, France ([olivier.bodic@chu-nantes.fr](mailto:olivier.bodic@chu-nantes.fr))

<sup>8</sup> CHRU de Tours, Pôle de Psychiatrie et d'Addictologie, Tours, France ([JB.COURTINE@chu-tours.fr](mailto:JB.COURTINE@chu-tours.fr))

\* Contributed equally to the study

† Corresponding Author: Wissam El-Hage, [wissam.elhage@univ-tours.fr](mailto:wissam.elhage@univ-tours.fr)

Dear editor,

Posttraumatic stress disorder (PTSD) affects 3.9% of the global population, with only half experiencing remission within three years without treatment [1,2]. Exposure therapy for PTSD aims to act on identified dysregulated brain regions [3]. Certainly, functional alterations occur in key brain regions of the fear-processing network, including the amygdala (AMY) [4] and the ventromedial prefrontal cortex (vmPFC) [5], a top-down control region engaged in extinction. Furthermore, the left dorsolateral PFC (dlPFC), known for cognitive control and emotion appraisal, is implicated in top-down control of the vmPFC [5] and in intrusive traumatic memories [6]. Moreover, stimulating this region could help with comorbid depressive symptoms. Combining exposure therapy with a neuromodulatory technique targeting the dlPFC is a logical proposition based on our understanding of PTSD-induced brain alterations, posttraumatic and comorbid depressive disorders. The integration of transcranial direct current stimulation (tDCS) into therapeutic practices, with its advantages of patient tolerance, cost-effectiveness, and easiness of availability, should be further explored. The technique involves applying a mild direct electrical current across the scalp, flowing electrons from an anode to a cathode. Consequently, our study aimed to explore whether multiple sessions of anodal tDCS over the left dlPFC during trauma exposures could diminish PTSD-related symptoms (*Figure 1A-B*), and achieve beneficial effects in a shorter timeframe.

Our study was a superiority randomized controlled trial involving 5 university hospital centers. All actors of the trial were kept blinded of treatment groups for study duration. Sixty-three participants (18-65 years old) suffering from chronic PTSD (3 months to 10 years), were recruited and allocated in a 1:1 ratio between two groups. The diagnosis of PTSD was established by a psychiatrist according to the DSM-5, confirmed by the Clinician Administration PTSD Scale for DSM-5 (CAPS-5). We excluded patients with severe visual or hearing impairment, neurological diseases, current addiction, pregnancy, intracranial metallic implants, psychotic disorders, or bipolar disorder. Randomization was stratified by center and depression severity, assessed using the Beck Depression Inventory (BDI) and categorized as  $BDI \leq 16$  or  $BDI > 16$ . The tDCS group received active stimulation (20 minutes at 2mA) during script exposure (two sessions per day, interspersed by 20-minute intervals, over five days). In comparison, the sham group received placebo stimulation (15 sec. ramp-up and down at session start and end) during the 10 script-exposure sessions. The script exposures, comprising factual, physical, and emotional elements, involved patients internally reading a self-written document accurately recalling the personal traumatic event [7]. The primary outcome was PTSD severity, assessed by the CAPS-5. The PTSD checklist scale (PCL-5) and BDI were secondary outcomes. All measures were apprehended at baseline, one (M1) and three months (M3) after the first treatment session. After one withdrawal of consent, 33 participants constituted the tDCS group and 29 participants the sham group.


A sample size of 64 participants yielded 80% statistical power to detect a 10-point difference between groups in the CAPS-5 score, assuming a standard deviation of 20 points, a correlation coefficient between repeated measures of a participant of 0.5 and a type I error set at 5%. Changes in every outcome over the follow-up period were compared between groups using a linear regression mixed-effect model. Fixed effects were for the time, for the treatment arm

and for the interaction term between time and treatment arm. We also included a subject random effect allowing for modelling the repeated measures in a same participant. Tests were two-sided and a p-value below 0.05 was considered significant. This study was approved (ANSM 2016-A01087-44; CPP 2016-R22) and registered (NCT02900053).

Sixty-two participants were included for analysis, from which 62 had contributed to measurements at baseline, 57 at M1, and 56 at M3. At baseline, the estimated mean CAPS-5 score was comparable between the Sham group ( $42.2 \pm 13.9$ ) and the tDCS group ( $46.4 \pm 11.6$ ) (*Figure 1C-D*). The CAPS-5 slope over the three-month period (from baseline to M3) was -7.2 points per month (95% CI -9.1 to -5.3) in the Sham group and -4.7 points per month (95% CI -6.5 to -2.9) in the tDCS group, with no significant difference between groups (the difference between groups was 2.5 points per month, 95% CI -0.2 to 5.1,  $p=0.064$ ). Concerning self-reported PTSD severity using the PCL-5, the outcomes aligned consistently with CAPS-5 scores. The PCL-5 slope over the 3 months was -6.8 points per month (95% CI -8.9 to -4.8) in the Sham group, and -4.2 points per month (95% CI -6.1 to -2.4) in the tDCS group, without significant difference between groups (2.6 points per month, 95% CI -0.2 to 5.3,  $p=0.068$ ). Additionally, for depressive comorbid symptoms, slope of the BDI score over the 3 months was -1.6 points per month (95% CI -2.4 to -0.8) in the sham tDCS group and -1.7 points per month (95% CI -2.5 to -0.9) in the tDCS group without significant difference between groups (the difference between groups was -0.1 point per month, 95% CI -1.2 to 1,  $p=0.837$ ). However, 10 tDCS sessions within five days were well tolerated and did not provoke any major adverse events.

No significant differences in the mean CAPS-5, PCL-5 or BDI scores were seen between groups. Consequently, our tDCS protocol targeting the left dlPFC might not be an appropriate protocol to combine with exposure therapy in PTSD patients when disease severity is evaluated at three months. Cathodal stimulation over the left dlPFC might have a greater influence in reducing PTSD symptoms and could be associated with anodal right dlPFC stimulation [8,9]. But the vmPFC could be further investigated as it was recently shown to reduce self-reported PTSD severity [10].

In conclusion, although well tolerated, active tDCS over the left dlPFC did not alleviate PTSD symptoms compared to sham stimulation. Anodal stimulation of the left dlPFC might not be efficacious in yielding beneficial effects when combined with script exposure. Further trials are needed, using different protocols and targeting other brain regions, to explore the efficacy of combining exposure procedures with tDCS.



**Figure 1.**

(A) Experimental design of anode-cathode positioning (EEG 10-20 system) and current application representation. The anode (in red) was placed over the F3 coordinate and the cathode (in blue) over FP2. Electrodes measured 35 cm<sup>2</sup> each. (B) Electromagnetic field modeling (magnE) according to electrodes positioning with a 2-mA current application. (C) Plots of means by group of the CAPS-5 measured at baseline (time=0), month 1 and month 3. Error bars are 95% confidence intervals. (D) Slopes of change from baseline of the CAPS-5 score over the 3 months period of the trial according to the group of randomization: slopes were estimated using a linear regression mixed effect model with time as a continuous variable and with an interaction term between time and group; colored shadows are the 95% confidence interval of the slopes.

## Contribution

This study was designed by Wissam El-Hage, Jean-Baptiste Courtine and Agnès Caille. They also actively conducted the study in association with HUGOPSY network, Ghina Harika-Germaneau, Olivier Bodic, Dominique Drapier, Bénédicte Gohier, Nematollah Jaafari, Anne Sauvaget, Samuel Bulteau, Valérie Gissot and Bruno Brizard. Data analysis was performed by Pierre Poupin and Agnès Caille. Noémie Eyraud and Marc Legrand prepared the manuscript. All authors revised and approved the final version of the paper.

## Funding

The authors are grateful for the invaluable contributions of the participants. The study was funded by Programme Hospitalier de Recherche Clinique Interrégional (PHRC-I) 2015. The study funder had no role to play in the study design, data collection, data analysis, data interpretation, or writing of the report.

## Declaration of competing interest

The authors declare having no conflicts of interest

## Data sharing statement

De-identified individual participant data will be made available to researchers who provide a methodologically sound proposal for use in achieving the goals of the approved proposal. A written agreement must be signed with the University Hospital of Tours and the coordinator of the study.

## References

- [1] Koenen KC, Ratanatharathorn A, Ng L, McLaughlin KA, Bromet EJ, Stein DJ, et al. Posttraumatic stress disorder in the World Mental Health Surveys. *Psychol Med* 2017;47:2260–74. <https://doi.org/10.1017/S0033291717000708>.
- [2] Morina N, Wicherts JM, Lobbrecht J, Priebe S. Remission from post-traumatic stress disorder in adults: A systematic review and meta-analysis of long term outcome studies. *Clin Psychol Rev* 2014;34:249–55. <https://doi.org/10.1016/j.cpr.2014.03.002>.
- [3] Manthey A, Sierk A, Brakemeier E-L, Walter H, Daniels JK. Does trauma-focused psychotherapy change the brain? A systematic review of neural correlates of therapeutic gains in PTSD. *Eur J Psychotraumatology* 2021;12:1929025. <https://doi.org/10.1080/20008198.2021.1929025>.
- [4] Yan X, Brown AD, Lazar M, Cressman VL, Henn-Haase C, Neylan TC, et al. Spontaneous brain activity in combat related PTSD. *Neurosci Lett* 2013;547:1–5. <https://doi.org/10.1016/j.neulet.2013.04.032>.
- [5] Kredlow, Alexandra M, Laurent ES, Ressler KJ, Phelps EA. Prefrontal cortex, amygdala, and threat processing: implications for PTSD. *Neuropsychopharmacology* 2022;47:247–59. <https://doi.org/10.1038/s41386-021-01155-7>.
- [6] Anderson MC, Ochsner KN, Kuhl B, Cooper J, Robertson E, Gabrieli SW, et al. Neural systems underlying the suppression of unwanted memories. *Science* 2004;303:232–5. <https://doi.org/10.1126/science.1089504>.
- [7] Thierrée S, Raulin-Briot M, Legrand M, Le Gouge A, Vancappel A, Tudorache A-C, et al. Combining Trauma Script Exposure With rTMS to Reduce Symptoms of Post-Traumatic Stress Disorder: Randomized Controlled Trial. *Neuromodulation J Int Neuromodulation Soc* 2021. <https://doi.org/10.1111/ner.13505>.
- [8] Asthana M, Nueckel K, Mühlberger A, Neueder D, Polak T, Domschke K, et al. Effects of Transcranial Direct Current Stimulation on Consolidation of Fear Memory. *Front Psychiatry* 2013;4.
- [9] Yosephi MH, Ehsani F, Daghighi M, Zoghi M, Jaberzadeh S. The effects of transcranial direct current stimulation intervention on fear: A systematic review of literature. *J Clin Neurosci Off J Neurosurg Soc Australas* 2019;62:7–13. <https://doi.org/10.1016/j.jocn.2019.01.011>.
- [10] van 't Wout-Frank M, Arulpragasam AR, Faucher C, Aiken E, Shea MT, Jones RN, et al. Virtual Reality and Transcranial Direct Current Stimulation for Posttraumatic Stress Disorder: A Randomized Clinical Trial. *JAMA Psychiatry* 2024. <https://doi.org/10.1001/jamapsychiatry.2023.5661>.